Cathie's Ark Logo
Veracyte Inc Logo

ARKK Holdings of Veracyte (VCYT) - Updated Daily

BioinformaticsGenomics
Date
Direction
Shares
Fund Weight
Fund
December 16, 2022
SELL18.274k0.0075%ARKK
December 15, 2022
SELL37.746k0.0151%ARKK
December 14, 2022
SELL59.838k0.0254%ARKK
January 21, 2022
BUY47.300k0.0102%ARKK
January 6, 2022
BUY29.411k0.0069%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
1.37%$1.55b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
22🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
22$14.27
🎫ARK Ownership Percent
6.6%
Description
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Website
www.veracyte.com

Other ETFs That Hold VCYT

Ticker
NameWeight
GNOMGlobal X Genomics & Biotechnology ETF2.88%
ARKGARK Genomic Revolution ETF2.65%
ARKKARK Innovation ETF1.49%
ARKWARK Next Generation Internet ETF1.46%
XBISPDR® S&P Biotech ETF0.88%
IBBiShares Biotechnology ETF0.16%